Literature DB >> 28889091

MRI in sarcoglycanopathies: a large international cohort study.

Giorgio Tasca1, Mauro Monforte1, Jordi Díaz-Manera2,3, Giacomo Brisca4, Claudio Semplicini5, Adele D'Amico6, Fabiana Fattori6, Anna Pichiecchio7, Angela Berardinelli8, Lorenzo Maggi9, Elio Maccagnano10,11, Nicoline Løkken12, Chiara Marini-Bettolo13, Francina Munell14, Angel Sanchez15, Nahla Alshaikh16, Nicol C Voermans17, Jahannaz Dastgir18, Dmitry Vlodavets19, Jana Haberlová20, Gianmichele Magnano21, Maggie C Walter22, Susana Quijano-Roy23, Robert-Yves Carlier24, Baziel G M van Engelen17, John Vissing12, Volker Straub13, Carsten G Bönnemann18, Eugenio Mercuri25, Francesco Muntoni16, Elena Pegoraro5, Enrico Bertini6, Bjarne Udd26,27,28, Enzo Ricci1, Claudio Bruno4.   

Abstract

OBJECTIVES: To characterise the pattern and spectrum of involvement on muscle MRI in a large cohort of patients with sarcoglycanopathies, which are limb-girdle muscular dystrophies (LGMD2C-2F) caused by mutations in one of the four genes coding for muscle sarcoglycans.
METHODS: Lower limb MRI scans of patients with LGMD2C-2F, ranging from severe childhood variants to milder adult-onset forms, were collected in 17 neuromuscular referral centres in Europe and USA. Muscle involvement was evaluated semiquantitatively on T1-weighted images according to a visual score, and the global pattern was assessed as well.
RESULTS: Scans from 69 patients were examined (38 LGMD2D, 18 LGMD2C, 12 LGMD2E and 1 LGMD2F). A common pattern of involvement was found in all the analysed scans irrespective of the mutated gene. The most and earliest affected muscles were the thigh adductors, glutei and posterior thigh groups, while lower leg muscles were relatively spared even in advanced disease. A proximodistal gradient of involvement of vasti muscles was a consistent finding in these patients, including the most severe ones.
CONCLUSIONS: Muscle involvement on MRI is consistent in patients with LGMD2C-F and can be helpful in distinguishing sarcoglycanopathies from other LGMDs or dystrophinopathies, which represent the most common differential diagnoses. Our data provide evidence about selective susceptibility or resistance to degeneration of specific muscles when one of the sarcoglycans is deficient, as well as preliminary information about progressive involvement of the different muscles over time. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28889091     DOI: 10.1136/jnnp-2017-316736

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A).

Authors:  Andrea Barp; Pascal Laforet; Luca Bello; Giorgio Tasca; John Vissing; Mauro Monforte; Enzo Ricci; Ariane Choumert; Tanya Stojkovic; Edoardo Malfatti; Elena Pegoraro; Claudio Semplicini; Roberto Stramare; Olivier Scheidegger; Jana Haberlova; Volker Straub; Chiara Marini-Bettolo; Nicoline Løkken; Jordi Diaz-Manera; Jon A Urtizberea; Eugenio Mercuri; Martin Kynčl; Maggie C Walter; Robert Y Carlier
Journal:  J Neurol       Date:  2019-09-25       Impact factor: 4.849

2.  Value of structured reporting in neuromuscular disorders.

Authors:  Francesco Alessandrino; Lara Cristiano; Claudia Maria Cinnante; Tommaso Tartaglione; Simonetta Gerevini; Tommaso Verdolotti; Giovanna Stefania Colafati; Emanuele Ghione; Raimondo Vitale; Lorenzo Peverelli; Claudia Brogna; Angela Berardinelli; Maurizio Moggio; Eugenio M Mercuri; Anna Pichiecchio
Journal:  Radiol Med       Date:  2019-03-09       Impact factor: 3.469

3.  Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.

Authors:  Mauro Monforte; Sara Bortolani; Eleonora Torchia; Lara Cristiano; Francesco Laschena; Tommaso Tartaglione; Enzo Ricci; Giorgio Tasca
Journal:  J Neurol       Date:  2021-09-06       Impact factor: 4.849

4.  First Identification of Rare Exonic and Deep Intronic Splice-Altering Variants in Patients With Beta-Sarcoglycanopathy.

Authors:  Zhiying Xie; Chengyue Sun; Chang Liu; Xujun Chu; Qiang Gang; Meng Yu; Yiming Zheng; Lingchao Meng; Fan Li; Dongliang Xia; Li Wang; Ying Li; Jianwen Deng; He Lv; Zhaoxia Wang; Wei Zhang; Yun Yuan
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

5.  Ambulatory Duchenne muscular dystrophy children: cross-sectional correlation between function, quantitative muscle ultrasound and MRI.

Authors:  Hala Abdulhady; Hossam M Sakr; Nermine S Elsayed; Tamer A El-Sobky; Nagia Fahmy; Amr M Saadawy; Heba Elsedfy
Journal:  Acta Myol       Date:  2022-03-31

6.  Identification of a novel SGCA missense mutation in a case of limb-girdle muscular dystrophy 2D with the absence of four sarcoglycan proteins.

Authors:  Yanpeng Lu; Xueqin Song; Guang Ji; Hongran Wu; Duan Li; Shuyan Sun
Journal:  Neuropathology       Date:  2019-04-15       Impact factor: 1.906

7.  The value of qualitative muscle MRI in the diagnostic procedures of myopathies: a biopsy-controlled study in 191 patients.

Authors:  Diana Lehmann Urban; Mohamed Mohamed; Albert C Ludolph; Jan Kassubek; Angela Rosenbohm
Journal:  Ther Adv Neurol Disord       Date:  2021-02-26       Impact factor: 6.570

Review 8.  Current and Future Approaches to Classify VUSs in LGMD-Related Genes.

Authors:  Chengcheng Li; Gabe Haller; Conrad C Weihl
Journal:  Genes (Basel)       Date:  2022-02-19       Impact factor: 4.096

9.  Progression to Loss of Ambulation Among Patients with Autosomal Recessive Limb-girdle Muscular Dystrophy: A Systematic Review.

Authors:  Ivana F Audhya; Antoinette Cheung; Shelagh M Szabo; Emma Flint; Conrad C Weihl; Katherine L Gooch
Journal:  J Neuromuscul Dis       Date:  2022

10.  Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials.

Authors:  Matteo Garibaldi; Tommaso Nicoletti; Elisabetta Bucci; Laura Fionda; Luca Leonardi; Stefania Morino; Laura Tufano; Girolamo Alfieri; Antonio Lauletta; Gioia Merlonghi; Alessia Perna; Salvatore Rossi; Enzo Ricci; Jorge Alonso Perez; Tommaso Tartaglione; Antonio Petrucci; Elena Maria Pennisi; Marco Salvetti; Gary Cutter; Jordi Díaz-Manera; Gabriella Silvestri; Giovanni Antonini
Journal:  Eur J Neurol       Date:  2021-12-06       Impact factor: 6.288

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.